Verseon Corporation Additional Listing & Total Voting Rights (0693V)

TIDMVERS

RNS Number : 0693V

Verseon Corporation

04 April 2019

April 4, 2019

Verseon Corporation

("Verseon" or the "Company")

Additional Listing & Total Voting Rights

Fremont, Calif.-Verseon, a technology-based pharmaceutical company, announces that application has been made for 171,974 new shares of common stock ("Common Shares") of par value $0.001 each to be admitted to trading on AIM pursuant to regularly scheduled vesting of restricted stock units and grant of restricted stock award (the "Issuance").

Of the 171,974 Common Shares issued, 8,474 shares were issued to Dr. Hecht, and 150,000 of the Common Shares were issued to Dr. Kim, both non-executive Directors of the Company, in relation to the payment of their Director's fees. Dr. Kim's shares are subject to a period of restriction of three years starting on November 5, 2018, the day Dr. Kim joined Verseon's Board of Directors, and expiring with respect to 1/12 of the shares at the end of each three-month period.

Following the Issuance, Dr. Hecht will hold 98,517 Common Shares, representing 0.06% of the Company's issued share capital and Dr. Kim will hold 150,000 Common Shares representing 0.09% of the Company's issued share capital.

The 171,974 new Common Shares issued pursuant to the Issuance will rank pari passu with the Company's existing Common Shares and admission to trading on AIM is expected to take place on April 9, 2019 ("Admission").

Total Voting Rights

Following Admission, the issued share capital of the Company will consist of 159,571,387 Common Shares and the Company will hold 42,917 shares in treasury. Therefore, the total number of Common Shares in the Company with voting rights will be 159,528,470. This figure may be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change in their interest in, the share capital of the Company under the FCA's Disclosure and Transparency Rules.

-Ends-

For further information, please contact

 
 Verseon Corporation                        www.verseon.com 
                                            +1 (510) 225 
 Sebastian Wykeham / Tina Schlafly           9000 
 
 Arden Partners (NOMAD and Joint Broker) 
 Ruari McGirr / Ciaran Walsh/ Alex           [phone] 
  Penny                                       5900 
 
 Cantor Fitzgerald Europe (Joint Broker) 
                                            [phone] 
 Phil Davies                                 7000 
 

For financial and business media enquiries, please contact

 
 Buchanan Communications Ltd (PR Advisers) 
                                              [phone] 
 Henry Harrison-Topham / Jamie Hooper          5000 
 

For trade and pharma media enquiries, please contact

 
 Vane Percy & Roberts 
                         +44 (0) 1737 
 Simon Vane Percy         821 890 
 
 
 1     Details of the person discharging managerial responsibilities 
        / person closely associated 
 a)    Name                            Dr. Thomas Hecht 
      ------------------------------  ------------------------------------ 
 2     Reason for the notification 
      -------------------------------------------------------------------- 
 a)    Position/status                 Non-Executive Chairman 
      ------------------------------  ------------------------------------ 
 b)    Initial notification            Initial notification 
        /Amendment 
      ------------------------------  ------------------------------------ 
 3     Details of the issuer, emission allowance market participant, 
        auction platform, auctioneer or auction monitor 
      -------------------------------------------------------------------- 
 a)    Name                            Verseon Corporation 
      ------------------------------  ------------------------------------ 
 b)    LEI                             213800CB2DUHDL6EPW12 
      ------------------------------  ------------------------------------ 
 4     Details of the transaction(s): section to be repeated 
        for (i) each type of instrument; (ii) each type of transaction; 
        (iii) each date; and (iv) each place where transactions 
        have been conducted 
      -------------------------------------------------------------------- 
 a)    Description of the              Restricted stock grant of Common 
        financial instrument,           Shares of par value $0.001 
        type of instrument 
 
        Identification code             ISIN: USU9221J1098 
      ------------------------------  ------------------------------------ 
 b)    Nature of the transaction       Vesting of restricted stock units 
      ------------------------------  ------------------------------------ 
 c)    Price(s) and volume(s)            Price(s)    Volume(s) 
                                          Nil         8,474 
                                                     ---------- 
      ------------------------------  ------------------------------------ 
       Aggregated information 
 
        - Aggregated volume              8,474 
 
 
 d)     - Price                          - 
      ------------------------------  ------------------------------------ 
 e)    Date of the transaction         31 March 2019 
      ------------------------------  ------------------------------------ 
 f)    Place of the transaction        N/a 
      ------------------------------  ------------------------------------ 
 
 
 1     Details of the person discharging managerial responsibilities 
        / person closely associated 
 a)    Name                            Dr. Sangtae Kim 
      ------------------------------  ------------------------------------ 
 2     Reason for the notification 
      -------------------------------------------------------------------- 
 a)    Position/status                 Non-Executive Director 
      ------------------------------  ------------------------------------ 
 b)    Initial notification            Initial notification 
        /Amendment 
      ------------------------------  ------------------------------------ 
 3     Details of the issuer, emission allowance market participant, 
        auction platform, auctioneer or auction monitor 
      -------------------------------------------------------------------- 
 a)    Name                            Verseon Corporation 
      ------------------------------  ------------------------------------ 
 b)    LEI                             213800CB2DUHDL6EPW12 
      ------------------------------  ------------------------------------ 
 4     Details of the transaction(s): section to be repeated 
        for (i) each type of instrument; (ii) each type of transaction; 
        (iii) each date; and (iv) each place where transactions 
        have been conducted 
      -------------------------------------------------------------------- 
 a)    Description of the              Restricted stock grant of Common 
        financial instrument,           Shares of par value $0.001 
        type of instrument 
 
        Identification code             ISIN: USU9221J1098 
      ------------------------------  ------------------------------------ 
 b)    Nature of the transaction       Restricted Stock Award 
      ------------------------------  ------------------------------------ 
 c)    Price(s) and volume(s)            Price(s)    Volume(s) 
                                          Nil         150,000 
                                                     ---------- 
      ------------------------------  ------------------------------------ 
       Aggregated information 
 
        - Aggregated volume              150,000 
 
 
 d)     - Price                          - 
      ------------------------------  ------------------------------------ 
 e)    Date of the transaction         2 April 2019 
      ------------------------------  ------------------------------------ 
 f)    Place of the transaction        N/a 
      ------------------------------  ------------------------------------ 
 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

END

MSCEAALDEANNEAF

(END) Dow Jones Newswires

April 04, 2019 02:01 ET (06:01 GMT)